Hans-Jürgen Möller

Psychiatry and Mental health · 2002–2016

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Psychiatry and Mental health — 79 citations into it; #1,071 of 1,338 by trust here, #469 by citations
• Endocrinology, Diabetes and Metabolism — 43 citations into it; #473 of 623 by trust here, #437 by citations
• Neurology — 9 citations into it

Whom Hans-Jürgen Möller trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. John W. Newcomer (in Psychiatry and Mental health)

Who trusts Hans-Jürgen Möller

1. I. Graham (in Psychiatry and Mental health)

Papers from Hans-Jürgen Möller's perspective

Ordered by how strongly the researchers Hans-Jürgen Möller trusts endorse each paper. Same corpus, a different order for every researcher.

1. Second-Generation (Atypical) Antipsychotics and Metabolic Effects (CNS Drugs)
2. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. (Schizophrenia Research)
3. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. (New England Journal of Medicine)
4. Physical health monitoring of patients with schizophrenia. (American Journal of Psychiatry)
5. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. (New England Journal of Medicine)
6. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. (New England Journal of Medicine)
7. Size of burden of schizophrenia and psychotic disorders. (European Neuropsychopharmacology)
8. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. (The Lancet)
9. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. (American Journal of Psychiatry)
10. Schizophrenia and increased risks of cardiovascular disease. (American Heart Journal)

Their papers

• Large recurrent microdeletions associated with schizophrenia (2008) — 1,814 citations
• Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology (2016) — 1,023 citations
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012) — 600 citations
• Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) — 2,329 citations
• Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level (2011) — 854 citations
• Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009) — 892 citations
• Common variants conferring risk of schizophrenia (2009) — 1,753 citations
• Identification of loci associated with schizophrenia by genome-wide association and follow-up (2008) — 1,107 citations
• The neural basis of the P300 potential (2004) — 105 citations
• Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection (2004) — 629 citations
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision (2002) — 778 citations